drugset / Trial / NCT07311148
A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This phase 2 study in China will evaluate the immunogenicity and safety of the Recombinant Zoster Vaccine, LYB004 in adults aged 40 years and older.
Timeline
- Start
- 2025-10-23
- Primary completion
- 2026-01
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LYB004 | Vaccine | 25 ug | Intramuscular |
| Subject | LYB004 | Vaccine | 50 ug | Intramuscular |
| Subject | LYB004 | Vaccine | 0.5 ml | Intramuscular |
| Subject | Shingrix | Vaccine | 50 ug | Intramuscular |
| Subject | Shingrix | Vaccine | 0.5 ml | Intramuscular |